Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Franco Conforti (Southamtpon, United Kingdom), Franco Conforti, Elizabeth Davies, Mark Jones, Claire Calderwood, Aiman Alzetani, Paul Skipp, Jane Warner, Philip Molyneaux, David Smart, Teresa Tetley, Tom Havelock, Toby Maher, Thomas Thatcher, Summet Mahajan, Benjamin Marshall, Luca Richeldi, Patricia Sime, Katherine O’Reilly, Donna Davies. Evaluation of romidepsin (FK228) as a potential therapy for idiopathic pulmonary fibrosis (IPF). Eur Respir J 2016; 48: Suppl. 60, 4039

Member's Comments

No comment yet.

Related content which might interest you: Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone Source: International Congress 2014 – ILDs 1 Year: 2014 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Pemetrexed in advanced non-small cell lung cancer patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Neoplasia in patients with ILD; shortened survival Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Effect of pirfenidone on IPF progression Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Novel lung function tests in patients with interstitial lung disease (ILD) Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 High-dose N-acetylcysteine (NAC) in fibrotic interstitial lung diseases, a retrospective analysis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Pulmonary thromboembolism (PE) in patients with interstitial lung diseases (ILD) Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2014 – ILDs 1 Year: 2014 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Steroid treatment effect in pulmonary sarcoidosis (STEPS study) Source: International Congress 2015 – Sarcoidosis: clinical Year: 2015 IGFBP-2 a new interesting target in IPF Source: International Congress 2016 – ILD pathogenesis Year: 2016 The effect of dasatinib, a novel tyrosine kinase inhibitor, on the regression of pulmonary fibrosis in mice Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Lung cancer as a comorbidity in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Pulmonary manifestations of systemic diseases Year: 2012 Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP) Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013